Pages that link to "Q42050398"
Jump to navigation
Jump to search
The following pages link to Optimal dose of oral omeprazole for maximal 24 hour decrease of intragastric acidity (Q42050398):
Displaying 50 items.
- Gastrin and Gastric Cancer (Q30238683) (← links)
- Personal review: is profound acid inhibition safe? (Q33815745) (← links)
- Gastroesophageal reflux disease and Barrett's esophagus (Q34057539) (← links)
- Omeprazole inhibits colorectal carcinogenesis induced by azoxymethane in rats (Q34377608) (← links)
- Effect of omeprazole on intragastric bacterial counts, nitrates, nitrites, and N-nitroso compounds (Q34378850) (← links)
- Omeprazole in the treatment of erosive oesophagitis refractory to high dose cimetidine and ranitidine (Q34392389) (← links)
- Treatment of refractory peptic ulcer with omeprazole or continued H2 receptor antagonists: a controlled clinical trial (Q34394586) (← links)
- Omeprazole 10 mg or 20 mg once daily in the prevention of recurrence of reflux oesophagitis. Solo Investigator Group (Q34407769) (← links)
- Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis (Q34409644) (← links)
- Marked increase in gastric acid secretory capacity after omeprazole treatment (Q34410460) (← links)
- Double blind comparison of the effects of cimetidine, ranitidine, famotidine, and placebo on intragastric acidity in 30 normal volunteers (Q34528705) (← links)
- Effect of omeprazole and cimetidine on prepyloric gastric ulcer: double blind comparative trial (Q34528890) (← links)
- A single night time dose of ranitidine in the acute treatment of gastric ulcer: a European multicentre trial (Q34529855) (← links)
- Effect of 'weekend therapy' with omeprazole on basal and stimulated acid secretion and fasting plasma gastrin in duodenal ulcer patients (Q34531831) (← links)
- Double blind multicentre comparison of omeprazole 20 mg once daily versus ranitidine 150 mg twice daily in the treatment of cimetidine or ranitidine resistant duodenal ulcers (Q34532362) (← links)
- Randomised, double blind comparison of omeprazole and cimetidine in the treatment of symptomatic gastric ulcer (Q34532837) (← links)
- Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders (Q34594257) (← links)
- Sufotidine 600 mg bd virtually eliminates 24 hour intragastric acidity in duodenal ulcer subjects (Q34998772) (← links)
- Acid Secretion, 1932-92: Advances, Adaptations, and Paradoxes (Q35192788) (← links)
- Long-term safety of proton pump inhibitors: risks of gastric neoplasia and infections (Q35194532) (← links)
- Progress with proton pump inhibition (Q35242583) (← links)
- Erosive oesophagitis: outcome of repeated long term maintenance treatment with low dose omeprazole 10 mg or placebo (Q35352817) (← links)
- Mucin gene expression in Barrett's oesophagus: an in situ hybridisation and immunohistochemical study (Q35362159) (← links)
- Use of Proton Pump Inhibitors and the Risk of Hospitalization for Infectious Gastroenteritis (Q36229626) (← links)
- The Many Faces of Reflux: Understanding the mechanisms of gastroesophageal reflux. (Q36283868) (← links)
- Does H2 receptor antagonist-resistant ulcer exist?--A review based on bioavailability in man. (Q36293265) (← links)
- Omeprazole drug interaction studies (Q36890310) (← links)
- DNA fingerprints of Helicobacter pylori before and after treatment with omeprazole (Q37106254) (← links)
- Omeprazole. Overview and opinion (Q37674515) (← links)
- The relationship among proton pump inhibitors, bone disease and fracture (Q37877712) (← links)
- Safety by design (Q37912552) (← links)
- Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II). (Q37944771) (← links)
- Systematic review: symptoms of rebound acid hypersecretion following proton pump inhibitor treatment (Q38073333) (← links)
- Therapeutic achlorhydria and risk of gastric cancer. (Q38710457) (← links)
- Does long-term profound inhibition of gastric acid secretion increase the risk of ECL cell-derived tumors in man? (Q38731421) (← links)
- Lansoprazole in the treatment of heartburn in patients without erosive oesophagitis (Q39438220) (← links)
- Wrong-way swallowing as a possible cause of bronchitis in patients with gastroesophageal reflux disease (Q39493732) (← links)
- Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: The U.S. multicenter study (Q39504404) (← links)
- Omeprazole versus placebo in duodenal ulcer healing. The United States experience (Q39519780) (← links)
- Omeprazole (40 mg) is superior to ranitidine in short-term treatment of ulcerative reflux esophagitis (Q39532250) (← links)
- Optimal reduction of gastric acid secretion in the treatment of peptic ulceration (Q39534703) (← links)
- The treatment of gastric ulcer with antisecretory drugs. Relationship of pharmacological effect to healing rates (Q39637298) (← links)
- Therapeutic progress--review XXIV. Are we making progress? The treatment of peptic ulcer disease by control of gastric acidity (Q39655748) (← links)
- Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome (Q39741061) (← links)
- Relationship between gastric secretion and infection (Q39758320) (← links)
- Achlorhydria: hypergastrinaemia: carcinoids--a flawed hypothesis? (Q39768924) (← links)
- Severe reflux esophagitis. (Q40563875) (← links)
- Pathophysiological effects of long-term acid suppression in man. (Q40595597) (← links)
- Oral proton-pump inhibitors and step-down therapy for nonulcer dyspepsia: is this the right approach? (Q41174311) (← links)
- Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease (Q41445264) (← links)